Palbociclib | PD 0332991 | 帕布昔利布 | CDK | AmBeed-信号通路专用抑制剂

首页 / / / / Palbociclib

帕博西尼 /Palbociclib {[allProObj[0].p_purity_real_show]}

货号：A295334 同义名： 帕布昔利布 / PD 0332991

Palbociclib是一种高度特异性的Cdk4和Cdk6抑制剂，IC50分别为11 nM和16 nM。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Palbociclib 化学结构
CAS号：571190-30-2

Palbociclib 3D分子结构
CAS号：571190-30-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Palbociclib 纯度/质量文件产品仅供科研

货号：A295334 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]; • Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]; • Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]; 更多 >

CDK 亚型比较

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 hydrochloride	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											SGK,ERK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinA, IC50: 70 nM CDK2/CyclinE, IC50: 35 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(A144C), Kd: 9.7 nM CDK2(C118L), Kd: 18.6 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	99%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinA, IC50: 4 nM CDK2/CyclinE, IC50: 3 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinA, IC50: 8 nM CDK2/CyclinE, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinA, IC50: 45 nM CDK2/CyclinE, IC50: 363 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinA, IC50: 0.68μM CDK2/CyclinE, IC50: 7.5μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinA, IC50: 38 nM CDK2/CyclinE, IC50: 48 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 hydrochloride	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	99%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinA, IC50: 0.7 μM CDK2/CyclinE, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 dihydrochloride									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				99%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinA, IC50: 224 nM CDK2/CyclinE, IC50: 2.54 μM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			99+%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ CLK4, IC50: 136 nM Dyrk1B , IC50: 1648 nM		99%+
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Palbociclib 生物活性

靶点	CDK4 CDK4/CyclinD1, IC50:11 nM CDK4/CyclinD3, IC50:9 nM CDK6 CDK6/CyclinD2, IC50:15 nM
描述	Palbociclib (PD 0332991) is an orally active, selective inhibitor of CDK4 and CDK6, showing IC50 values of 11 nM and 16 nM respectively. It exhibits strong anti-proliferative properties and is capable of inducing cell cycle arrest in cancer cells. This makes it a valuable agent in the study of HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma^[1].^[3].^[4].
体内研究	When administered orally at doses of 75 or 150 mg/kg daily for 14 days, Palbociclib leads to rapid tumor regressions and delays in tumor growth^[1]. An oral dose of 90 mg/kg daily for 12 days decreases Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes of tumor-free mice, indicating its effects independent of tumors^[2]. At a dose of 100 mg/kg administered daily for one week, Palbociclib demonstrates significant anti-tumor activity in a genetically engineered mosaic mouse model of liver cancer^[4].
体外研究	In laboratory tests, Palbociclib (0-1 μM, over 24 hours) inhibits Rb phosphorylation at Ser795 in MDA-MB-435 cells with an IC50 of 0.063 μM. It shows comparable effects on phosphorylation at both Ser780 and Ser795 in Colo-205 colon carcinoma cells^[1]. Additionally, Palbociclib (0-10 μM, over 24 hours) specifically arrests MDA-MB-453 breast cancer cells in the G1 phase^[1]. Over a period of 7 days, a 500 nM concentration of Palbociclib boosts the expression of homologous genes (H2d1, H2k1, and B2m) in MDA-MB-453 and MDA-MB-361 cells^[2]. Palbociclib inhibits growth in various luminal ER-positive and HER2-amplified breast cancer cell lines when applied at concentrations from 0-1 μM for 6 days, with IC50 values ranging between 4 nM and 1 μM^[3]. In human liver cancer cell lines, Palbociclib (0-1 μM, over 3 days) restricts proliferation with IC50 values from 0.01 μM to 3.49 μM and induces reversible cell cycle arrest^[4].
作用机制	Palbociclib can inhibit CDK4/6 in an ATP-competitive manner through its pyridopyrimidine structure^[1]^[3]^[4].

Palbociclib 动物研究

Dose

Rat: 25 mg/kg^[6] (i.p.); 1 mg/kg - 5 mg/kg^[5] (i.v.) Mice: 100 mg/kg^[7] (i.g., b.w.), 25 mg/kg - 125 mg/kg^[8] (p.o.), 5 mg/kg - 200 mg/kg^[5] (p.o.)

Administration

i.p., i.g., p.o.

Pharmacokinetics

Animal	Rats^[5]
Dose	5 mg/kg
Administration	i.v. or p.o.
V_d	7070 ml/kg (i.v.)
T_1/2	2.60 h (i.v.) 2.3 h (p.o.)
T_max	0.08 h (i.v.) 3.5 h (p.o.)
CL	37 ml/min/kg (i.v.)
C_max	2507 ng/ml (i.v.) 178 ng/ml (p.o.)
AUC_0→t	2160 ng·h/ml (i.v.) 1140 ng·h/ml (p.o.)

Palbociclib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03007979	Breast Cancer ... 展开 >> Breast Carcinoma Cancer of Breast Malignant Tumor of Breast 收起 <<	Phase 2	Recruiting	June 30, 2021	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia X Ma, M.D., Ph.D. 314-362-9383 cynthiaxma@wustl.edu Principal Investigator: Cynthia X Ma, M.D., Ph.D. Sub-Investigator: Foluso O Ademuyiwa, M.D. Sub-Investigator: Ron Bose, M.D., Ph.D. Sub-Investigator: Mathew Cherian, M.D. Sub-Investigator: Ashley Frith, M.D. Sub-Investigator: Leonel Hernandez Aya, M.D. Sub-Investigator: Peter Oppelt, M.D. Sub-Investigator: Haeseong Park, M.D. Sub-Investigator: Caron Rigden, M.D. Sub-Investigator: Rama Suresh, M.D. Sub-Investigator: Katherine Weilbaecher, M.D. Sub-Investigator: Rebecca Aft, M.D., Ph.D. Sub-Investigator: Lindsay Peterson, M.D. United States, Nebraska University of Nebraska Recruiting Lincoln, Nebraska, United States, 68588 Contact: Jairam Krishnamurthy, M.D. 402-559-1800 jairam.krishnamurthy@unmc.edu Principal Investigator: Jairam Krishnamurthy, M.D. Sub-Investigator: Kenneth Cowan, M.D. Sub-Investigator: Elizabeth Reed, M.D. Sub-Investigator: Pavankumar Tandra, M.D. 收起 <<
NCT01907607	Advanced Gastrointestinal Stro... 展开 >>mal Tumors 收起 <<	Phase 2	Active, not recruiting	April 2019	France ... 展开 >> Institut Bergonié Bordeaux, Gironde, France, 33076 Centre Georges-Francois Leclerc Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Hôpital de la Timone - AP-HM Marseille, France, 13385 Centre René Gauducheau Nantes, France, 44805 Hôpital Saint-Antoine (AP-HP) Paris, France, 75571 CHU de REIMS - Hôpital Robert Debré Reims, France, 51092 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT03304080	Breast Neoplasms ... 展开 >> Breast Diseases 收起 <<	Phase 1 Phase 2	Recruiting	November 1, 2019	United States, New York ... 展开 >> Mount Sinai Beth Israel Comprehensive Cancer Center West Recruiting New York, New York, United States, 10011 Contact: Paula Klein, MD 212-604-6021 paula.klein@mountsinai.org Perlmutter Cancer Center NYU Langone Not yet recruiting New York, New York, United States, 10016 Contact: Sylvia Adams, MD 212-731-5795 sylvia.adams@nyumc.org Sub-Investigator: Sylvia Adams, MD Mount Sinai West Recruiting New York, New York, United States, 10019 Contact: Krystal Cascetta, MD 212-523-8692 krystal.cascetta@mountsinai.org New York Presbyterian Herbert Irving Comprehensive Cancer Center at Columbia University Not yet recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD 212-305-1945 Kk2693@columbia.edu New York Presbyterian Meyer Cancer Center at Weill Cornell Not yet recruiting New York, New York, United States, 10065 Contact: Eleni Andreopoulou, MD 646-962-9888 ela9082@med.cornell.edu 收起 <<

Palbociclib 参考文献

[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475.

[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.

[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296.

Palbociclib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.17mL

2.23mL

1.12mL

22.34mL

4.47mL

2.23mL

Palbociclib 技术信息

CAS号	571190-30-2
分子式	C₂₄H₂₉N₇O₂
分子量	447.533

别名	帕布昔利布 ;PD 0332991
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,Room Temperature

溶解度

DMSO: 10 mg/mL(22.34 mM)，配合低频超声，水浴加热至45℃，并调节pH至4，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

0.1 M HCL: 25 mg/mL(55.86 mM)，配合低频超声，并调节pH至4

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03007979	Breast Cancer ... 展开 >> Breast Carcinoma Cancer of Breast Malignant Tumor of Breast 收起 <<	Phase 2	Recruiting	June 30, 2021	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia X Ma, M.D., Ph.D. 314-362-9383 cynthiaxma@wustl.edu Principal Investigator: Cynthia X Ma, M.D., Ph.D. Sub-Investigator: Foluso O Ademuyiwa, M.D. Sub-Investigator: Ron Bose, M.D., Ph.D. Sub-Investigator: Mathew Cherian, M.D. Sub-Investigator: Ashley Frith, M.D. Sub-Investigator: Leonel Hernandez Aya, M.D. Sub-Investigator: Peter Oppelt, M.D. Sub-Investigator: Haeseong Park, M.D. Sub-Investigator: Caron Rigden, M.D. Sub-Investigator: Rama Suresh, M.D. Sub-Investigator: Katherine Weilbaecher, M.D. Sub-Investigator: Rebecca Aft, M.D., Ph.D. Sub-Investigator: Lindsay Peterson, M.D. United States, Nebraska University of Nebraska Recruiting Lincoln, Nebraska, United States, 68588 Contact: Jairam Krishnamurthy, M.D. 402-559-1800 jairam.krishnamurthy@unmc.edu Principal Investigator: Jairam Krishnamurthy, M.D. Sub-Investigator: Kenneth Cowan, M.D. Sub-Investigator: Elizabeth Reed, M.D. Sub-Investigator: Pavankumar Tandra, M.D. 收起 <<
NCT01907607	Advanced Gastrointestinal Stro... 展开 >>mal Tumors 收起 <<	Phase 2	Active, not recruiting	April 2019	France ... 展开 >> Institut Bergonié Bordeaux, Gironde, France, 33076 Centre Georges-Francois Leclerc Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Hôpital de la Timone - AP-HM Marseille, France, 13385 Centre René Gauducheau Nantes, France, 44805 Hôpital Saint-Antoine (AP-HP) Paris, France, 75571 CHU de REIMS - Hôpital Robert Debré Reims, France, 51092 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT03304080	Breast Neoplasms ... 展开 >> Breast Diseases 收起 <<	Phase 1 Phase 2	Recruiting	November 1, 2019	United States, New York ... 展开 >> Mount Sinai Beth Israel Comprehensive Cancer Center West Recruiting New York, New York, United States, 10011 Contact: Paula Klein, MD 212-604-6021 paula.klein@mountsinai.org Perlmutter Cancer Center NYU Langone Not yet recruiting New York, New York, United States, 10016 Contact: Sylvia Adams, MD 212-731-5795 sylvia.adams@nyumc.org Sub-Investigator: Sylvia Adams, MD Mount Sinai West Recruiting New York, New York, United States, 10019 Contact: Krystal Cascetta, MD 212-523-8692 krystal.cascetta@mountsinai.org New York Presbyterian Herbert Irving Comprehensive Cancer Center at Columbia University Not yet recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD 212-305-1945 Kk2693@columbia.edu New York Presbyterian Meyer Cancer Center at Weill Cornell Not yet recruiting New York, New York, United States, 10065 Contact: Eleni Andreopoulou, MD 646-962-9888 ela9082@med.cornell.edu 收起 <<
NCT02778685	Estrogen Receptor Positive ... 展开 >> HER2/Neu Negative Postmenopausal Recurrent Breast Carcinoma Stage IV Breast Cancer 收起 <<	Phase 2	Recruiting	February 2019	United States, California ... 展开 >> City of Hope Corona Recruiting Corona, California, United States, 92879 Contact: Cheryl Corpus 626-256-4673 ext 81529 Sub-Investigator: Misagh Karimi, MD City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Yuan Yuan, MD, PhD 800-826-4673 Principal Investigator: Yuan Yuan, MD, PhD City of Hope Antelope Valley Recruiting Lancaster, California, United States, 93534 Contact: Regan Johnson 626-256-4673 ext 25648 Sub-Investigator: Mohammad Fekrazad, MD City of Hope Mission Hills Recruiting Mission Hills, California, United States, 91345 Contact: Amy Shousha 626-256-4673 ext 81865 Sub-Investigator: Suzy Melkonian, MD City of Hope Rancho Cucamonga Recruiting Rancho Cucamonga, California, United States, 91730 Contact: Valerie Estala 626-256-4673 ext 81699 Sub-Investigator: Behnam Ebrahimi, MD City of Hope South Pasadena Recruiting South Pasadena, California, United States, 91030 Contact: Odessa Rodriguez 626-256-4673 ext 81409 Sub-Investigator: Christina Yeon, MD City of Hope West Covina Recruiting West Covina, California, United States, 91790 Contact: Mei Zheng 626-256-4673 ext 81336 Sub-Investigator: Gargi Upadhyaya, MD 收起 <<
NCT02059330	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT01701375	-		Terminated(Material sponsor wi... 展开 >>thdrew support) 收起 <<	-	-
NCT02536742	Metastatic Breast Cancer	Phase 2	Recruiting	January 2020	Belgium ... 展开 >> Sint-Augustinus Recruiting Antwerpen, Belgium, 2610 Contact: Luc Dirix cto@gza.be Principal Investigator: Luc Dirix Institut Jules Bodet Recruiting Brussels, Belgium, 1000 Contact: Michail Ignatiadis michail.ignatiadis@bordet.be Principal Investigator: Michail Ignatiadis Cliniques Universitaires Saint-Luc Recruiting Brussels, Belgium, 1200 Contact: Francois Duhoux francois.duhoux@uclouvain.be Principal Investigator: Francois Duhoux Antwerp University Hospital Recruiting Edegem, Belgium, 2650 Contact: Konstantinos Papadimitriou Principal Investigator: Konstantinos Papadimitriou UZ Leuven Recruiting Leuven, Belgium Contact: Patrick Neven Principal Investigator: Patrick Neven CHU Liege Recruiting Liège, Belgium Contact: Guy Jerusalem g.jerusalem@chu.ulg.ac.be Principal Investigator: Guy Jerusalem Clinique St. Elizabeth Recruiting Namur, Belgium, 5000 Contact: Peter Vuylsteke peter.vuylsteke@cmsenamur.be Principal Investigator: Peter Vuylsteke Italy Ospedali degli Infermi, S.O.C. Oncologia Recruiting Biella, Italy, 13879 Contact: Elena Seles, MD seles.e@libero.it Principal Investigator: Elena Seles, MD Ospedale Centrale Bolzano, Medical Oncology Recruiting Bolzano, Italy Contact: Claudio Graiff claudio.graiff@sabes.it Principal Investigator: Claudio Graiff IRCCS San Martino University Hospital Not yet recruiting Genova, Italy Contact: Alberto Ballestrero aballestrero@unige.it Principal Investigator: Alberto Ballestrero Mater Salutis Hospital AULSS 21 della Regione Veneto Recruiting Legnago, Italy Contact: Andrea Bonetti andrea.bonetti@aulsslegnago.it Principal Investigator: Andrea Bonetti Istituto Europeo di Oncologia Recruiting Milano, Italy Contact: Marco Colleoni marco.colleoni@ieo.it Principal Investigator: Marco Colleoni Istituti Clinici Scientifici Maugeri, Medical Oncology Unit Recruiting Pavia, Italy, 27100 Contact: Antonio Bernardo antonio.bernardo@icsmaugeri.it Principal Investigator: Antonio Bernardo, MD Azienda USL4 Prato Recruiting Prato, Italy Contact: Luca Malorni lmalorni@usl4.toscana.it Principal Investigator: Luca Malorni, MD PhD United Kingdom UH Bristol NHS Foundation Trust Not yet recruiting Bristol, United Kingdom Principal Investigator: Jeremy Braybrooke Velindre NHS Trust Not yet recruiting Cardiff, United Kingdom Principal Investigator: Jacinta Abraham Western General Hospital Not yet recruiting Edinburgh, United Kingdom Principal Investigator: Dave Cameron Beatson West of Scotland Cancer Centre Not yet recruiting Glasgow, United Kingdom Principal Investigator: Iain Macpherson Singleton Hospital Not yet recruiting Swansea, United Kingdom Principal Investigator: Gianfilippo Bertelli Royal Cornwall Not yet recruiting Truro, United Kingdom Principal Investigator: Alastair Thomson 收起 <<
NCT02142868	-		-	-	-
NCT01701375	Relapsed Acute Leukemia ... 展开 >> Refractory Acute Leukemia High-Risk Myelodysplasia 收起 <<	Phase 1	Terminated(Material sponsor wi... 展开 >>thdrew support) 收起 <<	-	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21287 United States, New York Weill Cornell Medical Center New York, New York, United States, 10065 收起 <<
NCT02760030	Estrogen Receptor and/or Proge... 展开 >>sterone Receptor Positive HER2/Neu Negative Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer 收起 <<	Phase 2	Recruiting	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Megan Laibach Thomason 614-366-0115 Megan.Laibachthompson@osumc.edu Principal Investigator: Nicole Williams 收起 <<
NCT03377101	Estrogen Receptor Positive ... 展开 >> HER2/Neu Negative Progesterone Receptor Positive Stage IV Breast Cancer AJCC v6 and v7 收起 <<	Phase 2	Withdrawn(change in study desi... 展开 >>gn.) 收起 <<	-	-
NCT02764541	Breast Cancer	Phase 2	Recruiting	November 2019	United States, Connecticut ... 展开 >> Stamford Hospital Recruiting Stamford, Connecticut, United States, 06904 Contact: K.M. Steve Lo, MD slo@stamhealth.org United States, Maine Eastern Maine Medical Center Recruiting Brewer, Maine, United States, 04412 Contact: Thomas H. Openshaw, MD topenshaw@emhs.org United States, Massachusetts Dana-Farber at St. Elizabeth's Medical Center Recruiting Boston, Massachusetts, United States, 02135 Contact: Caroline Block, MD caroline_block@dfci.harvard.edu Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Steven Come, MD 617-667-4599 scome@bidmc.harvard.edu Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Otto F Metzger, MD 617-632-3800 ometzger@partners.org Principal Investigator: Otto F Metzger, MD DF/BWCC at Milford Regional Medical Center Recruiting Milford, Massachusetts, United States, 01757 Contact: Michael Constantine, MD michael_constantine@dfci.harvard.edu DF/BWCC in clinical affiliation with South Shore Hospital Recruiting South Weymouth, Massachusetts, United States, 02190 Contact: Meredith Faggen, MD meredith_faggen@dfci.harvard.edu United States, Rhode Island Lifespan Recruiting Providence, Rhode Island, United States, 02903 Contact: Mary Anne Fenton, MD mfenton@lifespan.org United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Denise A. Yardley, MD dyardley@tnonc.com Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Ingrid Mayer, MD ingrid.mayer@vanderbilt.edu 收起 <<
NCT02041273	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT02692755	Hormone Receptor Positive HER-... 展开 >>2 Negative Breast Cancer 收起 <<	Phase 2 Phase 3	Recruiting	December 2019	United States, District of Col... 展开 >>umbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Nellie Novielli, RN 202-784-3923 noviella@georgetown.edu Contact: Julie Castle, RN 2026872209 bickmorj@georgetown.edu Principal Investigator: Filipa Lynce, MD MedStar Washington Hospital Center Recruiting Washington, District of Columbia, United States, 20013 Contact: Gouled Ahmed 202-877-9374 Gouled.A.Ahmed@medstar.net Principal Investigator: Christopher Gallagher United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Simona Olberkyte 773-834-9114 solberkyte@medicine.bsd.uchicago.edu Principal Investigator: Olwen Hahn, MD United States, Maryland MedStar Union Memorial Hospital Recruiting Baltimore, Maryland, United States, 21218 Contact: Barbara Rector 410-261-8151 Principal Investigator: Mahsa Mohebtash, MD MedStar Good Samaritan Hospital Recruiting Baltimore, Maryland, United States, 21239 Contact: Barbara Rector 410-261-8151 Principal Investigator: Lois Kamugisha, MD United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Rita Murphy 215-955-9626 Rita.murphy@jefferson.edu Principal Investigator: Maysa Abu-Khalaf, MD 收起 <<
NCT02065063	Cancer	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 收起 <<
NCT01976169	Advanced Breast Cancer	Phase 1	Recruiting	December 2020	United States, Texas ... 展开 >> UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: Barbara Haley, MD 214-648-4180 barbara.haley@utsouthwestern.edu Contact: Gregg Wright 214-648-7097 James.Wright@UTSouthwestern.edu Sub-Investigator: Dawn Klemow, MD Sub-Investigator: Erik Knudsen, MD Sub-Investigator: Navid Sadeghi, MD Sub-Investigator: Lori Watumull, MD Principal Investigator: Barbara Haley, MD 收起 <<
NCT03065387	Malignant Neoplasm of Breast ... 展开 >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites Malignant Neoplasms of Independent (Primary) Multiple Sites Malignant Neoplasms of Lip Oral Cavity and Pharynx Malignant Neoplasms of Mesothelial and Soft Tissue Malignant Neoplasms of Respiratory and Intrathoracic Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands Malignant Neoplasms of Urinary Tract Neoplasms of Uncertain or Unknown Behavior 收起 <<	Phase 1	Recruiting	October 2023	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact spihapau@mdanderson.org 收起 <<
NCT01918176	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site South Miami, Florida, United States, 33143 收起 <<
NCT02592746	Metastatic Breast Cancer	Phase 2	Recruiting	June 2021	Korea, Republic of ... 展开 >> Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of, 135-710 Contact: Yeon-Hee Park, MD, Ph.D 82-2-3410-1780 yeonh.park@samsung.com Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Yeon Hee Park 收起 <<
NCT02222441	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 收起 <<
NCT02785939	CCND1 Gene Amplification ... 展开 >> CCND2 Gene Amplification CCND3 Gene Amplification CDK4 Gene Amplification Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7 收起 <<	Phase 2 Phase 3	Active, not recruiting	April 1, 2022	-
NCT03079011	Metastatic Breast Cancer	Phase 3	Recruiting	April 15, 2024	France ... 展开 >> Centre Leon Berard Not yet recruiting Lyon, France Contact: Thomas BACELOT, MD - PhD + 33 (0)4 78 78 26 54 thomas.bachelot@lyon.unicancer.fr Principal Investigator: Thomas Bachelot, MD - PhD Institut Curie Recruiting Paris, France, 75005 Contact: François-Clément BIDARD, MD- PhD + 33 (0)1 44 32 40 00 fcbidard@curie.fr Principal Investigator: François-Clément BIDARD, MD - PhD Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Suzette DELALOGE, MD + 33 (0)1 42 11 42 93 Suzette.Delaloge@gustaveroussy.fr Principal Investigator: Suzette DELALOGE, MD 收起 <<
NCT02499146	Advanced Breast Cancer	Phase 1	Active, not recruiting	January 26, 2020	China, Beijing ... 展开 >> Beijing Cancer Hospital/Oncology department Beijing, Beijing, China, 100142 China, Guangdong Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China, 510060 Guangdong General Hospital/Department of Breast Surgery Guangzhou, Guangdong, China, 510080 China, Heilongjiang Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081 China, Jilin The first hospital of jilin university Changchun, Jilin, China, 130021 China, Zhejiang The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310003 China Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, China, 100021 收起 <<
NCT02297438	Breast Neoplasms	Phase 3	Active, not recruiting	December 2, 2022	-
NCT01536743	Ovarian Epithelial Carcinoma	Phase 2	Active, not recruiting	May 10, 2020	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095 收起 <<
NCT01227434	Glioblastoma ... 展开 >>Gliosarcoma Anaplastic Astrocytoma 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94143 收起 <<
NCT03159195	-		Recruiting	September 30, 2019	United States, New York ... 展开 >> Pfizer, Inc. Recruiting New York, New York, United States, 10017 收起 <<
NCT01227434	-		Terminated	-	-
NCT02871791	Human Epidermal Growth Factor ... 展开 >>2 Negative Carcinoma of Breast Hormone Receptor (HR)-Positive Breast Cancer 收起 <<	Phase 1 Phase 2	Recruiting	July 2021	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, MD, MPH 617-632-2335 stolaney@partners.org Principal Investigator: Sara Tolaney, MD, MPH 收起 <<
NCT03709082	HER2-positive Breast Cancer ... 展开 >> Breast Cancer Metastatic 收起 <<	Phase 1 Phase 2	Recruiting	October 15, 2025	United States, Kansas ... 展开 >> The University of Kansas Cancer Center, West Clinic Recruiting Kansas City, Kansas, United States, 66112 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu The University of Kansas Cancer Center, Westwood Campus Recruiting Kansas City, Kansas, United States, 66205 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu The University of Kansas Cancer Center, Overland Park Clinic Recruiting Overland Park, Kansas, United States, 66210 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu United States, Missouri The University of Kansas Cancer Center, North Clinic Recruiting Kansas City, Missouri, United States, 64154 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu The University of Kansas Cancer Center, Lee's Summit Clinic Recruiting Lee's Summit, Missouri, United States, 64064 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu 收起 <<
NCT01821066	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT02605486	Metastatic Breast Cancer (MBC)	Phase 1 Phase 2	Recruiting	November 2020	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Ayca Gucalp, MD 646-888-4536 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Ayca Gucalp, MD 646-888-4536 收起 <<
NCT02730429	Endometrial Cancer	Phase 2	Recruiting	December 2022	Denmark ... 展开 >> NSGO Recruiting Copenhagen, Sjaelland, Denmark, 2100 Contact: Pernille Strøm, RN pernille.stroem@regionh.dk 收起 <<
NCT02917005	Metastatic Breast Cancer	Phase 2	Not yet recruiting	March 2022	-
NCT02690480	Breast Neoplasms	Phase 2	Recruiting	December 2022	Ireland ... 展开 >> Bon Secours Hospital Recruiting Cork, Ireland Beaumont Hospital Withdrawn Dublin, Ireland Mater Misericordiae University Hospital Recruiting Dublin, Ireland Mater Private Hospital Withdrawn Dublin, Ireland St. James´s Hospital Withdrawn Dublin, Ireland Galway University Hospital Recruiting Galway, Ireland University Hospital Limerick Withdrawn Limerick, Ireland University Hospital Waterford Recruiting Waterford, Ireland Spain Hospital Universitario Central de Asturias Recruiting Oviedo, Asturias, Spain, 33011 Hospital Universitari Son Espases Recruiting Palma de Mallorca, Baleares, Spain, 07120 Hospital Son Llàtzer Recruiting Palma De Mallorca, Baleares, Spain, 07198 Hospital Universitario Mutua Terrassa Recruiting Terrassa, Barcelona, Spain, 08221 Hospital Universitario Infanta Cristina Recruiting Parla, Madrid, Spain, 28981 Hospital Universitario Quirón de Madrid Recruiting Pozuelo de Alarcón, Madrid, Spain, 28223 Clínica Universidad de Navarra Withdrawn Pamplona, Navarra, Spain, 31008 Complejo Hospitalario Universitario Vigo Recruiting Vigo, Pontevedra, Spain, 36204 Hospital Universitario Sant Joan Reus Recruiting Reus, Tarragona, Spain, 43204 Centro Oncológico de Galicia Recruiting A Coruña, Spain, 15009 Hospital del Mar Recruiting Barcelona, Spain, 08003 Hospital de la Santa Creu y Sant Pau Recruiting Barcelona, Spain, 08026 Hospital Universitario Germans Trias i Pujol Recruiting Barcelona, Spain, 08916 Hospital Universitario Reina Sofía Recruiting Córdoba, Spain, 14004 Complejo Hospitalario de Jaén Recruiting Jaen, Spain, 23007 Complejo Asistencial Universitario de León Recruiting Leon, Spain, 24080 Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain, 28034 Hospital Clínico Universitario San Carlos Recruiting Madrid, Spain, 28040 Hospital Universitario de Fuenlabrada Recruiting Madrid, Spain, 28492 Hospital Regional Universitario de Málaga Recruiting Málaga, Spain, 29011 Hospital Universitario Virgen de la Macarena Recruiting Sevilla, Spain, 41009 Hospital Quirón Sagrado Corazón de Sevilla Recruiting Sevilla, Spain, 41013 Hospital Universitario Vírgen del Rocío Recruiting Sevilla, Spain, 41013 Hospital Universitario de Valme Recruiting Sevilla, Spain, 41014 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46010 Hospital General Universitario Valencia Recruiting Valencia, Spain, 46014 Hospital Universitario I Politècnic La Fe Recruiting Valencia, Spain, 46026 Hospital Universitario Miguel Servet Recruiting Zaragoza, Spain, 50009 收起 <<
NCT01291017	Non-small Cell Lung Cancer	Phase 2	Completed	-	United States, Florida ... 展开 >> UF Health Cancer Center Gainesville, Florida, United States, 32610 H. Lee Moffitt Cancer and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT02389842	Advanced Solid Tumours ... 展开 >> Breast Cancer 收起 <<	Phase 1	Unknown	August 2017	United Kingdom ... 展开 >> The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SM2 5PT Contact: Timothy Yap, PhD 02086613539 timothy.yap@icr.ac.uk Principal Investigator: Timothy Yap, PhD The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Anne Amstrong, MBBS 0161 446 3746 elaine.mercer@christie.nhs.uk Principal Investigator: Anne Armstrong, MBBS 收起 <<
NCT03573648	Breast Cancer	Phase 2	Recruiting	August 2020	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials HopkinsBreastTrials@jhmi.edu Contact: Kimmel Cancer Center Clinical Research Office 410-955-8866 jhcccro@jhmi.edu Principal Investigator: Cesar A Santa-Maria, MD, MSCI 收起 <<
NCT03355157	Metastatic Breast Cancer	Phase 4	Recruiting	December 31, 2021	Germany ... 展开 >> Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe Recruiting Frankfurt am Main, Germany, 60431 Contact: Marc Thill, MD, PhD marc.thill@fdk.info 收起 <<
NCT03147287	Metastatic Breast Cancer	Phase 2	Recruiting	December 31, 2024	United States, Maine ... 展开 >> Eastern Maine Medical Center Recruiting Bangor, Maine, United States, 04401 Contact: Zarah Lucas, MD zdlucas@emhs.org United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Erica L Mayer, MD MPH 617-632-2335 emayer@partners.org Principal Investigator: Erica L. Mayer, MD MPH Dana-Farber at St. Elizabeth's Medical Center Recruiting Brighton, Massachusetts, United States, 02135 Contact: Caroline Block, MD caroline_block@dfci.harvard.edu DF/BWCC at Milford Regional Medical Center Recruiting Milford, Massachusetts, United States, 01757 Contact: Michael Constantine, MD michael_constantine@dfci.harvard.edu DF/BWCC in clinical affiliation with South Shore Hospital Recruiting South Weymouth, Massachusetts, United States, 02190 Contact: Meredith Faggen, MD meredith_faggen@dfci.harvard.edu United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia Ma, MD cynthiaxma@wustl.edu United States, New Hampshire Dana-Farber/New Hampshire Oncology-Hematology Recruiting Londonderry, New Hampshire, United States, 03053 Contact: Fred Briccetti, MD fred_briccetti@dfci.harvard.edu 收起 <<
NCT03219554	Thymic Cancer	Phase 2	Not yet recruiting	December 2020	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT02942355	Female Breast Carcinoma	Phase 2	Recruiting	October 2022	United States, North Carolina ... 展开 >> Levine Cancer Institute Recruiting Charlotte, North Carolina, United States, 28204 Contact: Wendy Vandermolen 收起 <<
NCT03471663	Breast Cancer	Phase 1	Recruiting	October 2020	United States, Colorado ... 展开 >> Local Institution Recruiting Aurora, Colorado, United States, 80012 Contact: Site 105 United States, Tennessee Local Institution Recruiting Nashville, Tennessee, United States, 37203-1619 Contact: Site 102 United States, Texas Local Institution Recruiting Dallas, Texas, United States, 75246 Contact: Site 106 Local Institution Recruiting San Antonio, Texas, United States, 78217 Contact: Site 104 Local Institution Recruiting Tyler, Texas, United States, 75702 Contact: Site 103 United States, Washington Local Institution Recruiting Tacoma, Washington, United States, 98405-5093 Contact: Site 101 收起 <<
NCT01291017	-		Completed	-	-
NCT02040857	Breast Cancer	Phase 2	Active, not recruiting	June 2019	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94115 United States, Indiana Indiana University Health Hospital Indianapolis, Indiana, United States, 46202 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 MGH/North Shore Cancer Center Danvers, Massachusetts, United States, 01923 DF/DWCC at Milford Regional Cancer Center Milford, Massachusetts, United States, 01757 South Shore Hospital Weymouth, Massachusetts, United States, 02190 United States, New Hampshire Dana-Farber/New Hampshire Oncology-Hematology Londonderry, New Hampshire, United States, 03053 United States, Pennsylvania University of Pennsylvania-Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT03774472	Anatomic Stage I Breast Cancer... 展开 >> AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor Positive HER2/Neu Negative MKI67 Positive Postmenopausal Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 收起 <<	Phase 1 Phase 2	Recruiting	December 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Debasish Tripathy 713-794-4385 Principal Investigator: Debasish Tripathy 收起 <<
NCT03024489	Head and Neck Cancer ... 展开 >> Locally Advanced Unresectable 收起 <<	Phase 1 Phase 2	Recruiting	December 2026	Thailand ... 展开 >> Faculty of Medicine, Ramathibodi Hospital Recruiting Bangkok, Thailand, 10400 Contact: Somthawin Lukerak +66-2-201-1671 somthawin.aie@mahidol.ac.th 收起 <<
NCT02679755	Breast Cancer	Phase 4	Recruiting	June 2019	Australia, New South Wales ... 展开 >> Alexander David Guminski Recruiting North Sydney, New South Wales, Australia, 2060 Alexander Maxwell Menzies Recruiting North Sydney, New South Wales, Australia, 2060 Benjamin Carl Forster Recruiting North Sydney, New South Wales, Australia, 2060 Frances Mary Boyle Recruiting North Sydney, New South Wales, Australia, 2060 HPS Pharmacies - North Sydney Recruiting North Sydney, New South Wales, Australia, 2060 Mater Hospital Sydney Recruiting North Sydney, New South Wales, Australia, 2060 Royal North Shore Hospital - Clinical Trials Pharmacy Recruiting St Leonards, New South Wales, Australia, 2065 Royal North Shore Hospital Recruiting St Leonards, New South Wales, Australia, 2065 Pathology North-RNS Recruiting Sydney, New South Wales, Australia, 2065 Australia, Queensland Icon Cancer Care Wesley Recruiting Auchenflower, Queensland, Australia, 4066 River City Pharmacy Recruiting Auchenflower, Queensland, Australia, 4066 Icon Cancer Care Chermside Recruiting Chermside, Queensland, Australia, 4032 Haematology & Oncology Clinics of Australia Pty Ltd trading as Icon Cancer Care Corporate Office Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Care South Brisbane Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Foundation Recruiting South Brisbane, Queensland, Australia, 4101 Icon Cancer Care Southport Recruiting Southport, Queensland, Australia, 4215 Australia, South Australia Flinders Medical Centre-Pharmacy Department Recruiting Bedford Park, South Australia, Australia, 5042 Flinders Medical Centre Recruiting Bedford Park, South Australia, Australia, 5042 Australia, Victoria Monash Health-Parmacy Recruiting Clayton, Victoria, Australia, 3168 Monash Health Recruiting Clayton, Victoria, Australia, 3168 Peter MacCallum Cancer Centre Pharmacy Recruiting Melbourne, Victoria, Australia, 3000 Sunshine Hospital Pharmacy - Clinical Trials Recruiting St Albans, Victoria, Australia, 3021 Sunshine Hospital Recruiting St Albans, Victoria, Australia, 3021 Australia, Western Australia Fiona Stanley Hospital Recruiting Murdoch, Western Australia, Australia, 6150 Pharmacy Department Recruiting Murdoch, Western Australia, Australia, 6150 India Rajiv Gandhi Cancer Institute And Research Centre Recruiting New Delhi, Delhi, India, 110 085 Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences Recruiting New Delhi, Delhi, India, 110029 The Gujarat Cancer & Research Institute Recruiting Ahmedabad, Gujarat, India, 380016 Manipal Hospital Recruiting Bangalore, Karnataka, India, 560017 HealthCare Global Enterprises Ltd. Recruiting Bangalore, Karnataka, India, 560027 Kasturba Hospital, Manipal Centre For Clinical Research Recruiting Manipal, Karnataka, India, 576104 Tata Memorial Centre, Tata Memorial Hospital Recruiting Mumbai, Maharashtra, India, 400 012 Meditrina Institute Of Medical Sciences Recruiting Nagpur, Maharashtra, India, 440012 Shatabdi Hospital Recruiting Nashik, Maharashtra, India, 422005 Deenanath Mangeshkar Hospital and Research Center Recruiting Pune, Maharashtra, India, 411 004 Sahyadri Speciality Hospital Recruiting Pune, Maharashtra, India, 411004 Apollo Speciality Hospital Recruiting Chennai, Tamilnadu, India, 600 035 收起 <<
NCT03709680	Solid Tumors ... 展开 >>Ewing Sarcoma Rhabdoid Tumor Rhabdomyosarcoma Neuroblastoma Medulloblastoma 收起 <<	Phase 1	Not yet recruiting	September 27, 2023	-
NCT02897375	Solid Neoplasm ... 展开 >> Stage III Pancreatic Cancer Stage IIIA Breast Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Breast Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Stage IV Non-Small Cell Lung Cancer Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer Sarcoma Colorectal Cancer Head and Neck Cancer Cancer of Unknown Primary Bladder Cancer Ovarian Cancer 收起 <<	Phase 1	Recruiting	December 2021	United States, Georgia ... 展开 >> Emory University/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Nakita Brown 404-616-9850 nlbrown@emory.edu Contact: Monique Williams 404-778-4383 monique.guyinn@emory.edu 收起 <<
NCT03560531	Breast Cancer	Phase 1	Recruiting	December 2020	United States, New York ... 展开 >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 收起 <<
NCT02905318	Prostate Cancer	Phase 2	Recruiting	December 2019	Canada, Alberta ... 展开 >> Cross Cancer Institute Recruiting Edmonton, Alberta, Canada, T6G 1Z2 Contact: Michael Kolinsky 780 432-8762 Canada, British Columbia BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Kim Chi 604 877-6000 ext 2746 Canada, Nova Scotia QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane 902 473-6106 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Som Mukherjee 905 387-9495 ext 64605 London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Eric W. Winquist 519 685-8261 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Michael Ong 613 737-7700 ext 75051 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Adrian Sacher 416 946-4501 ext 3550 Canada, Quebec CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal, Quebec, Canada, H2X 3E4 Contact: Fred Saad 514 890-8000 ext 27466 The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 Canada, Saskatchewan Allan Blair Cancer Centre Recruiting Regina, Saskatchewan, Canada, S4T 7T1 Contact: Muhammad Salim 306 766-2691 Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Nayyer Iqbal 306 655-2710 收起 <<
NCT02159755	CCND1 Positive ... 展开 >> Recurrent Mantle Cell Lymphoma t(11;14) 收起 <<	Phase 1	Active, not recruiting	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10065 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT02030483	Multiple Myeloma	Phase 1	Terminated(The company providi... 展开 >>ng one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.) 收起 <<	-	United States, New York ... 展开 >> Weill Cornell Medical College New York, New York, United States, 10065 收起 <<
NCT03423199	Breast Neoplasms	Phase 3	Recruiting	February 2022	Japan ... 展开 >> Aichi Cancer Center Hospital Recruiting Nagoya, Aichi, Japan, 464-8681 Contact: Hiroji Iwata, MD National Cancer Center Hospital East Recruiting Kashiwa, Chiba, Japan, 2778577 Contact: Hirofumi Mukai, MD, PhD National Hospital Organization Shikoku Cancer Center Recruiting Matsuyama, Ehime, Japan, 7910280 Contact: Kenjiro Aogi National Hospital Organization Hokkaido Cancer Center Recruiting Sapporo, Hokkaido, Japan, 0030804 Contact: Masato Takahashi, MD, PhD Hyogo Cancer Center Recruiting Akashi, Hyogo, Japan, 6738558 Contact: Koji Matsumoto, MD Kanagawa Cancer Center Recruiting Yokohama, Kanagawa, Japan, 2418515 Contact: Toshinari Yamashita, MD, PhD Kindai University Hospital Recruiting Ōsaka-sayama, Osaka, Japan, 5898511 Contact: Junji Tsurutani, MD, PhD Toranomon Hospital Recruiting Minato-Ku, Tokyo, Japan, 1058470 Contact: Toshimi Takano, MD Chiba Cancer Center Recruiting Chiba, Japan, 2608717 Contact: Naohito Yamamoto, MD, PhD Kyusyu Cancer Center Recruiting Fukuoka, Japan, 8111395 Contact: Eriko Tokunaga, MD National Hospital Organization Osaka National Hospital Recruiting Osaka, Japan, 5400006 Contact: Norikazu Masuda National Cancer Center Hospital Recruiting Tokyo, Japan, 104-0045 Contact: Kenji Tamura, MD, PhD Korea, Republic of National Cancer Center Recruiting Gyeonggi-do, Korea, Republic of, 10408 Contact: Keun Seok Lee, MD, PhD Ajou University Hospital Recruiting Gyeonggi-do, Korea, Republic of, 16499 Contact: Seok Yun Kang, MD Seoul National University Bundang Hospital Recruiting Gyeonggi-do, Korea, Republic of, 463-707 Contact: Jee Hyun Kim, MD, MS, PhD Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Kyung-Hun Lee, MS, PhD Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: Kyung Hae Jung, MD, PhD Severance Hospital, Yonsei University Health System Recruiting Soeul, Korea, Republic of, 03722 Contact: Joo Hyuk Sohn, MD Singapore National University Hospital Recruiting Singapore, Singapore, 119882 Contact: Soo Chin Lee, MMed, MRCP National Cancer Centre Singapore Recruiting Singapore, Singapore, 169610 Contact: Yoon Sim Yap, MD Taiwan National Taiwan University Hospital Recruiting Taipei, Taiwan, 10048 Contact: Yen-Shen Lu, PhD Taipei Vetarans General Hospital Recruiting Taipei, Taiwan, 11217 Contact: Ling-Ming Tseng, MD Sun Yat-Sen Cancer Center Recruiting Taipei, Taiwan, 11259 Contact: Mei-Ching Liu, MD 收起 <<
NCT03526250	Advanced Malignant Solid Neopl... 展开 >>asm RB1 Positive Recurrent Childhood Ependymoma Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Kidney Wilms Tumor Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Glioma Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Rhabdoid Tumor Recurrent Rhabdomyosarcoma Recurrent Soft Tissue Sarcoma Refractory Ependymoma Refractory Ewing Sarcoma Refractory Glioma Refractory Hepatoblastoma Refractory Langerhans Cell Histiocytosis Refractory Malignant Germ Cell Tumor Refractory Malignant Glioma Refractory Medulloblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Peripheral Primitive Neuroectodermal Tumor Refractory Rhabdoid Tumor Refractory Rhabdomyosarcoma Refractory Soft Tissue Sarcoma 收起 <<	Phase 2	Recruiting	March 30, 2023	-
NCT02774681	Breast Carcinoma Metastatic in... 展开 >> the Brain Estrogen Receptor Negative HER2/Neu Negative HER2/Neu Positive Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer 收起 <<	Phase 2	Recruiting	February 2020	United States, Illinois ... 展开 >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Cesar A. Santa-Maria 312-695-4520 cesar.santa-maria@northwestern.edu Principal Investigator: Cesar A. Santa-Maria, MD Northwestern Lake Forest Hospital Recruiting Lake Forest, Illinois, United States, 60045 Contact: Valerie Nelson, MD 847-582-2134 Principal Investigator: Valerie Nelson, MD United States, Texas Houston Methodist Hospital/Houston Methodist Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jenny Chang, MD 713-441-9948 Principal Investigator: Jenny Chang, MD 收起 <<
NCT02513394	Breast Cancer	Phase 3	Recruiting	September 2025	-
NCT03531645	Malignant Neoplasms of Female ... 展开 >>Genital Organs 收起 <<	Phase 2	Not yet recruiting	February 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact aajazaeri@mdanderson.org 收起 <<
NCT03498378	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 1	Recruiting	January 2022	United States, California ... 展开 >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Kathryn Gold, MD 收起 <<
NCT02255461	Childhood Choroid Plexus Tumor... 展开 >> Childhood Ependymoblastoma Childhood Grade III Meningioma Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Childhood Medulloepithelioma Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Anaplastic Oligoastrocytoma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Giant Cell Glioblastoma Recurrent Childhood Glioblastoma Recurrent Childhood Gliomatosis Cerebri Recurrent Childhood Gliosarcoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor 收起 <<	Phase 1	Recruiting	December 31, 2018	United States, California ... 展开 >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Girish Dhall 323-361-4629 gdhall@chla.usc.edu Principal Investigator: Girish Dhall Lucile Packard Children Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Paul G. Fisher 650-721-5889 pfisher@stanford.edu Principal Investigator: Paul G. Fisher United States, District of Columbia Childrens National Medical Center Recruiting Washington, District of Columbia, United States, 20010-2970 Contact: Eugene Hwang, MD 202-476-5046 ehwang@childrensnational.org Principal Investigator: Lindsay B Kilburn, MD Sub-Investigator: Roger Packer, MD Sub-Investigator: Brain Rood, MD Sub-Investigator: Eugene Hwang, MD United States, Illinois Lurie Childrens Hospital-Chicago Recruiting Chicago, Illinois, United States, 60614 Contact: Stewart Goldman 312-227-4874 sgoldman@luriechildrens.org Principal Investigator: Stewart Goldman, MD Sub-Investigator: Jason Fangusaro, MD Sub-Investigator: Rishi Lulla, MD Sub-Investigator: Natasha Pillay-Smiley, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira Dunkel 212-639-2153 dunkeli@mskcc.org Principal Investigator: Ira Dunkel United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: David Van Mater, MD, PhD 919-684-3401 david.vanmater@duke.edu Principal Investigator: David Van Mater United States, Ohio Cincinnati Children Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Maryam Fouladi 513-803-0721 maryam.fouladi@cchmc.org Principal Investigator: Maryam Fouladi United States, Pennsylvania Children Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Ian Pollack 412-692-5881 Pollaci@chp.edu Sub-Investigator: Ian Pollack, MD Principal Investigator: A. Kim Ritchey, MD United States, Tennessee St. Jude Children Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Giles Robinson, MD 901-595-2907 giles.robinson@stjude.org Principal Investigator: Zsila Sadighi, MD Sub-Investigator: Amar Gajjar, MD United States, Texas Texas Childrens Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia M. Baxter, MD 832-824-4681 pabaxter@txch.org Sub-Investigator: Murali M. Chintagumpala Principal Investigator: Patricia Baxter United States, Washington Seattle Children Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Sarah Leary 206-987-2106 sarah.leary@seattlechildrens.org Principal Investigator: Sarah Leary 收起 <<
NCT03478514	Mantle Cell Lymphoma ... 展开 >> B Cell Lymphoma 收起 <<	Phase 2	Recruiting	December 2022	United States, New York ... 展开 >> Weill Cornell Medical College Recruiting New York, New York, United States, 10065 Contact: Peter Martin United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: Kami Maddocks 收起 <<
NCT01209598	-		Completed	-	-
NCT03560856	Breast Cancer ... 展开 >> HR+/HER2-negative Breast Cancer Metastasis 收起 <<	Phase 2	Not yet recruiting	June 1, 2022	-
NCT03242382	Sarcoma Advan... 展开 >>ced Cancer 收起 <<	Phase 2	Recruiting	December 31, 2019	Spain ... 展开 >> Hospital de la Santa Creu i Sant Pau Active, not recruiting Barcelona, Spain Hospital Universitario 12 de Octubre Active, not recruiting Madrid, Spain Hospital Universitario Virgen de la Victoria Not yet recruiting Málaga, Spain Contact: Isabel Sevilla, MD Hospital Universitario Central de Asturias Not yet recruiting Oviedo, Spain Contact: Carlos Alvarez, MD Complejo Hospitalario Universitario de Santiago Not yet recruiting Santiago de Compostela, Spain Contact: Yolanda Vidal, MD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain, 41013 Contact: Javier Martín Broto Hospital Universitari i Politècnic La Fe Not yet recruiting Valencia, Spain Contact: Roberto Díaz, MD Hospital Universitario Miguel Servet Not yet recruiting Zaragoza, Spain Contact: Javier Martínez Trufero, md 收起 <<
NCT01953731	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT02131298	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT01209598	Sarcoma Lipos... 展开 >>arcoma 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT02806050	Breast Cancer	Phase 2	Active, not recruiting	November 2019	Netherlands ... 展开 >> University Medical Center Groningen Groningen, Netherlands, 9713 GZ 收起 <<
NCT03284957	Breast Cancer	Phase 1 Phase 2	Recruiting	October 21, 2020	United States, Massachusetts ... 展开 >> Investigational Site Number 8400002 Recruiting Boston, Massachusetts, United States, 02114 United States, New York Investigational Site Number 8400003 Recruiting New York, New York, United States, 10065 United States, Washington Investigational Site Number 8400001 Recruiting Seattle, Washington, United States, 98109 France Investigational Site Number 2500001 Recruiting Nantes, France, 44093 收起 <<
NCT03389477	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 2	Recruiting	June 30, 2026	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Douglas R Adkins, M.D. 314-362-4471 dadkins@wustl.edu Principal Investigator: Douglas R Adkins, M.D. Sub-Investigator: Olivia Aranha, M.D. Sub-Investigator: Mackenzie Daly, M.D. Sub-Investigator: Hiram Gay, M.D. Sub-Investigator: Ryan Jackson, M.D. Sub-Investigator: Peter Oppelt, M.D. Sub-Investigator: Randal Paniello, M.D. Sub-Investigator: Patrik Pipkorn, M.D. Sub-Investigator: Jason Rich, M.D. Sub-Investigator: Wade Thorstad, M.D. Sub-Investigator: Jose Zevallos, M.D., MPH 收起 <<
NCT02384239	Metastatic Breast Cancer ... 展开 >> Hormone Receptor Positive 收起 <<	Phase 2	Recruiting	August 2020	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94143 Contact: Amy DeLuca 415-353-7288 Amy.DeLuca@ucsf.edu Contact: Ivy Wong 415-353-7873 Ivy.Wong@ucsf.edu Principal Investigator: Hope Rugo, M.D. United States, District of Columbia Georgetown University Recruiting Washington, District of Columbia, United States, 20007 Contact: Nellie Novielli 202-784-3923 noviella@georgetown.edu Contact: Julie Castle 202-687-2209 bickmorj@georgetown.edu Principal Investigator: Claudine Issacs, MD United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Nana Owusu 773-702-2065 nowusu@medicine.bsd.uchicago.edu Contact: Glenna Smith 773-834-2143 gsmith6@bsd.uchicago.edu Principal Investigator: Rita Nanda, MD United States, Indiana Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Robbie Comito 317-274-0935 rcomito@iupui.edu Principal Investigator: Anna Maria Storniolo, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Bridget Walsh 410-502-3613 bwalsh9@jhmi.edu Principal Investigator: Vered Stearns, MD United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Lauren Fisher 617-632-4321 lfisher7@partners.org Contact: Nicole Ryabin 617-632-6767 Nicole_Ryabin@dfci.harvard.edu Principal Investigator: Erica Mayer, MD United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Richelle Pelton 734-763-2960 peltonr@med.umich.edu Principal Investigator: Catherine Van Poznak, MD United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37240 Contact: Mikala Barnes 615-875-0072 mikala.barnes@vanderbilt.edu Contact: Kathleen Sanders 615-343-4091 kathleen.sanders@Vanderbilt.Edu Principal Investigator: Ingrid Mayer, MD United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Claudette Foreman 713-798-7315 claudette.foreman@bcm.edu Contact: Anne Pavlick 713-798-7814 anne.pavlick@bcm.edu Principal Investigator: Polly Niravath, MD 收起 <<
NCT02499120	Squamous Cell Carcinoma of the... 展开 >> Head and Neck (SCCHN) 收起 <<	Phase 2	Active, not recruiting	June 21, 2019	-
NCT03170206	Lung Cancer	Phase 1 Phase 2	Recruiting	March 31, 2024	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Geoffrey Shapiro, MD, PhD 617-632-4942 Principal Investigator: Geoffrey Shapiro, MD Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Rebecca Heist, MD 617-726-1838 Principal Investigator: Rebecca Heist, MD 收起 <<
NCT03194373	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 2	Recruiting	July 3, 2021	United States, Indiana ... 展开 >> Indiana University Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Anya Kjeldsen 317-278-0779 amkjelds@iu.edu Principal Investigator: Greg Durm, MD United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Paul Swiecicki, M.D. 734-647-1017 pswiecic@umich.edu Principal Investigator: Paul Swiecicki, M.D. United States, Tennessee Vanderbilt University Not yet recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Michael Gibson, M.D. 收起 <<
NCT02311946	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> MRA Clinical Research - Phase 1 Miami, Florida, United States, 33143 Miami Research Associates, LLC South Miami, Florida, United States, 33143 MRA Clinical Research, LLC South Miami, Florida, United States, 33143 收起 <<
NCT03220191	Healthy Volunteer	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 收起 <<
NCT03472573	Recurrent B Acute Lymphoblasti... 展开 >>c Leukemia Refractory B Acute Lymphoblastic Leukemia 收起 <<	Phase 1	Recruiting	November 2020	United States, Pennsylvania ... 展开 >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Margaret Kasner, MD 215-955-8874 margaret.kasner@jefferson.edu Principal Investigator: Margaret Kasner, MD 收起 <<
NCT02022982	KRAS Mutant Non-Small Cell Lun... 展开 >>g Cancer Solid Tumors 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2020	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT03065062	Lung Cancer Squamous Cell ... 展开 >> Solid Tumors Head & Neck Cancer Pancreatic Cancer 收起 <<	Phase 1	Recruiting	January 2023	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Rebecca Heist, MD 617-726-1838 Principal Investigator: Rebecca Heist, MD Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02115 Contact: James Mier, MD 617-667-0430 Principal Investigator: James Mier, MD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Andrew Wolanski, NP 617-632-6623 awolanski@partners.org Principal Investigator: Geoffrey Shapiro, MD 收起 <<
NCT02448771	Breast Cancer Stage IV ... 展开 >> Unresectable Locally Advanced Invasive Breast Cancer Metastatic Invasive Breast Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	April 2022	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT02334800	Healthy, Hepatic Insufficiency	Phase 1	Completed	-	United States, Florida ... 展开 >> Orlando Clinical Research Center Orlando, Florida, United States, 32809 Weston Diagnostics (Ultrasound Facility) Orlando, Florida, United States, 32825 收起 <<
NCT03184090	Metastatic Breast Cancer	Phase 2	Recruiting	March 2019	Italy ... 展开 >> Ospedale Antonio Perrino Not yet recruiting Brindisi, Italy Contact: Saverio Cinieri Principal Investigator: Saverio Cinieri Istituto Europeo di Oncologia Not yet recruiting Milan, Italy Contact: Giuseppe Curigliano Principal Investigator: Giuseppe Curigliano Azienda Sanitaria Universitaria Integrata di Udine Not yet recruiting Udine, Italy Contact: Allesandro Minisini Principal Investigator: Allesandro Minisini Spain ICO Badalona Recruiting Badalona, Barcelona, Spain Contact: Vanesa Quiroga Principal Investigator: Vanesa Quiroga ICO l'Hospitalet Recruiting L'Hospitalet de Llobregat, Barcelona, Spain, 08007 Contact: Miguel Gil Principal Investigator: Miguel Gil Clinico Universitario A Coruña Recruiting A Coruña, Spain Contact: Lourdes Calvo Principal Investigator: Lourdes Calvo Hospital del Mar Recruiting Barcelona, Spain, 08003 Contact: Joan Albanell Principal Investigator: Joan Albanell Hospital Reina Sofia Recruiting Cordoba, Spain Contact: Juan De La Haba Principal Investigator: Juan De La Haba Hospital de Leon Recruiting Leon, Spain Contact: Andrés Garcia-Palomo Principal Investigator: Andres Garcia-Palomo Hospital 12 de Octubre Recruiting Madrid, Spain Contact: Eva Ciruelos Principal Investigator: Eva Ciruelos Hospital Clinico San Carlos Recruiting Madrid, Spain Contact: Jose Angel Garcia-Saenz Principal Investigator: Jose Angel Garcia-Saenz Hospital La Paz Recruiting Madrid, Spain Contact: Enrique Espinosa Principal Investigator: Enrique Espinosa Hospital Virgen del Rocío Recruiting Sevilla, Spain Contact: Manuel Ruiz Principal Investigator: Manuel Ruiz Hospital Clinico Universitario de Valencia Recruiting Valencia, Spain Contact: Begoña Bermejo Principal Investigator: Begoña Bermejo Hospital Universitari i Politecnic La Fe Recruiting Valencia, Spain Contact: Ana Santaballa Principal Investigator: Ana Santaballa Hospital Miguel Servet Recruiting Zaragoza, Spain Contact: Antonio Antón Principal Investigator: Antonio Antón 收起 <<
NCT02334800	-		Completed	-	-
NCT01864746	Breast Cancer ... 展开 >> Hormonreceptor Positive Her2-normal Postneoadjuvant Treatment With CDK 4/6 Inhibitor CPS-EG Score 收起 <<	Phase 3	Active, not recruiting	November 2023	United States, Pennsylvania ... 展开 >> NSABP Foundation Pittsburgh, Pennsylvania, United States, 15212 Australia, New South Wales Contact: Australia and New Zealand Breast Cancer Trials Group Newcastle, New South Wales, Australia, PO Box 155 Austria Contact: Austrian Breast & Colorectal Cancer Study Group Vienna, Austria, 1090 Canada Contact: NSABP Foundation Multiple Locations, Canada France Contact: UNICANCER Paris, France, 75654 Germany Contact: German Breast Group Neu-Isenburg, Germany, 63263 Ireland Contact: Cancer Trials Ireland Dublin, Ireland, 2 Japan Contact: Japan Breast Cancer Research Group Tokyo, Japan, 103-0016 Korea, Republic of Contact: Korea Cancer Study Group Seoul, Korea, Republic of, 138-736 Spain GEICAM San Sebastián de los Reyes, Spain, 28703 United Kingdom Contact: Institute of Cancer Research London, United Kingdom, SW7 3RP 收起 <<
NCT03454035	Tumor, Solid ... 展开 >>Pancreatic Cancer 收起 <<	Phase 1	Recruiting	October 24, 2023	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT03132454	Hematopoietic/Lymphoid Cancer ... 展开 >> Acute Myeloid Leukemia Acute Lymphoblastic Leukemia 收起 <<	Phase 1	Recruiting	July 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact tkadia@mdanderson.org 收起 <<
NCT02334527	Metastatic Urothelial Carcinom... 展开 >>a (UC) 收起 <<	Phase 2	Terminated(Data from first 12 ... 展开 >>subjects-primary endpoint not met. Data analysis underway.) 收起 <<	-	United States, Michigan ... 展开 >> University of Michigan Ann Arbor, Michigan, United States, 48109 United States, North Carolina North Carolina Cancer Hospital (UNC) Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT03285568	-		Completed	-	-
NCT03530696	HER2-positive Breast Cancer ... 展开 >> Breast Cancer Breast Cancer Stage Recurrent Breast Cancer Metastatic Breast Cancer HER2 Positive Breast Carcinoma 收起 <<	Phase 2	Not yet recruiting	August 1, 2022	-
NCT02334527	-		Terminated(Data from first 12 ... 展开 >>subjects-primary endpoint not met. Data analysis underway.) 收起 <<	-	-
NCT02738866	Metastatic Breast Cancer	Phase 2	Recruiting	January 2020	United States, District of Col... 展开 >>umbia Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Hopkins Breast Trials 410-955-8804 HopkinsBreastTrials@jhmi.edu Principal Investigator: Raquel Nunes, MD United States, Maryland Anne Arundel Health System Research Institute, Inc. Recruiting Annapolis, Maryland, United States, 21401 Principal Investigator: Jeanine Werner, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials 410-955-8804 HopkinsBreastTrials@jhmi.edu Principal Investigator: Vered Stearns, M.D. United States, Pennsylvania Allegheny Health Network (AHN) - Allegheny General Hospital ONLY Recruiting Pittsburgh, Pennsylvania, United States, 15212 Principal Investigator: Antonios Christou, MD Reading Hospital - McGlinn Cancer Institute Recruiting West Reading, Pennsylvania, United States, 19611 Principal Investigator: Terrence Cescon,, MD 收起 <<
NCT02896335	Metastatic Malignant Neoplasm ... 展开 >>to Brain 收起 <<	Phase 2	Recruiting	August 2022	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Priscilla Brastianos, MD 617-724-8770 PBRASTIANOS@mgh.harvard.edu Principal Investigator: Priscilla Brastianos, MD Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Eudocia K. Lee, MD 617-632-2166 Principal Investigator: Eudocia Lee, MD 收起 <<
NCT03454919	Melanoma	Phase 2	Not yet recruiting	June 30, 2020	-
NCT02600923	Advanced Breast Cancer Female	Phase 3	Recruiting	March 29, 2019	Argentina ... 展开 >> Instituto de Oncologia de Rosario Active, not recruiting Rosario, Santa FE, Argentina, S2000KZE Sanatorio Guemes Active, not recruiting Caba, Argentina, C1180AAX Hospital Italiano de Buenos Aires Active, not recruiting Caba, Argentina, C1181ACH Hospital Britanico de Buenos Aires Active, not recruiting Caba, Argentina, C1280AEB Instituto Medico Especializado Alexander Fleming Active, not recruiting Caba, Argentina, C1426ANZ Instituto de Cardiologia y Cirugia Cardiovascular Active, not recruiting Santa Fe, Argentina, S3000EPV ISIS Centro Especializado Active, not recruiting Santa Fe, Argentina, S3000FFU Brazil Hospital Da Cidade De Passo Fundo Recruiting Passo Fundo, RIO Grande DO SUL, Brazil, 99010-260 Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia Active, not recruiting Porto Alegre, RIO Grande DO SUL, Brazil, 90610-000 Oncologia Rede D'Or S.A. Active, not recruiting Rio de Janeiro, Brazil, 22271-110 IDOR - Instituto D'Or em Pesquisa e Ensino Active, not recruiting Rio de Janeiro, Brazil, 22281-100 Sociedade Beneficente de Senhoras Hospital Sirio Libanes Recruiting Sao Paulo, Brazil, 01308-050 Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda Recruiting São Paulo, Brazil, 01317-000 Colombia Instituto de Cancerologia S.A. Active, not recruiting Medellin, Antioquia, Colombia, 050034 Oncomedica S.A. Active, not recruiting Monteria, Cordoba, Colombia, 230003 Administradora Country Active, not recruiting Bogota, Distrito Capital, Colombia, 11001000 Oncology Center Active, not recruiting Bogota, Distrito Capital, Colombia, 110221162 Imagenes Diagnosticas Active, not recruiting Pereira, Risaralda, Colombia, 660001 ONCOLOGOS DEL OCCIDENTE S.A.S Sede Pereira Clinica de Alta Tecnologia Maraya Active, not recruiting Pereira, Risaralda, Colombia, 660001 Mexico Fucam A.C. Active, not recruiting Coyoacan, D.f., Mexico, 04890 Instituto Nacional de Cancerologia Active, not recruiting Tlalpan, D.f., Mexico, 14080 Hospital Maria Auxiliadora Active, not recruiting Guadalajara, Jalisco, Mexico, 44540 Clinica de Especialidades Medicas Intepro, ONCE Oncologia Especializada Active, not recruiting Zapopan, Jalisco, Mexico, 45030 Hospital Universitario Dr. Jose Eleuterio Gonzalez Active, not recruiting Monterrey, Nuevo LEON, Mexico, 64460 收起 <<
NCT02668666	Hormone Receptor Positive Mali... 展开 >>gnant Neoplasm of Breast Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Estrogen Receptor Positive Breast Cancer Progesterone Receptor Positive Tumor Metastatic Breast Cancer 收起 <<	Phase 2	Recruiting	June 2019	United States, Illinois ... 展开 >> University of Illinois Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Oana Danciu, M.D. Contact: Joanna Hill 312-996-9272 joanhill@uic.edu United States, Michigan Michigan State University Recruiting Lansing, Michigan, United States, 48910 Contact: Karen Luellen 517-975-9534 Karen.Luellen@hc.msu.eduu.edu Principal Investigator: Deimante Tamkus, M.D. United States, Minnesota University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski 612-624-0937 eezielin@umn.edu Principal Investigator: Anne Blaes, MD United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Jennifer Messick 402-321-1911 jennifer.messick@unmc.edu Principal Investigator: Pavan Kumar Tandra, MD United States, Pennsylvania Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Christina Rodriquez 717-531-5364 crodriguez1@hmc.psu.edu Principal Investigator: Cristina Truica, MD Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Sean Fleming 717-531-5364 sfleming1@pennstatehealth.psu.edu Principal Investigator: Cristina Truica, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53705 Contact: Cancer Connect 608-262-5223 cancerconnect@uwcarbone.wisc.edu Principal Investigator: Kari Wisinski, MD 收起 <<
NCT03439735	Breast Cancer	Phase 2	Recruiting	July 1, 2022	United States, Maryland ... 展开 >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Hopkins Breast Trials 410-614-1361 hopkinsbreasttrials@jhmi.edu Contact: Johns Hopkins Clinical Research Office 410-955-8866 JHCCCRO@jhmi.edu 收起 <<
NCT02530320	Oligodendroglioma ... 展开 >> Oligoastrocytoma 收起 <<	Phase 2	Recruiting	December 2018	Spain ... 展开 >> Hospital Insular de Canarias Recruiting Las Palmas de Gran Canaria, Las Palmas, Spain Contact: Elena Vicente 93 434 44 12 secretaria@geino.es Principal Investigator: Elena Vicente Hospital Son Espases Recruiting Palma de Mallorca, Mallorca, Spain Contact: Jose Fuster 93 434 44 12 secretaria@geino.es Principal Investigator: Jose Fuster Hospital Clínic de Barcelona Recruiting Barcelona, Spain Contact: Estela Pineda 93 434 44 12 secretaria@geino.es Principal Investigator: Estela Pineda ICO Hospitalet Recruiting Barcelona, Spain Contact: Miguel Gil Gil 93 434 44 12 secretaria@geino.es Principal Investigator: Miguel Gil Gil Hospital de León Not yet recruiting León, Spain Contact: Ángel Rodríguez 93 434 44 12 secretaria@geino.es Principal Investigator: Ángel Rodríguez Hospital 12 de Octubre Recruiting Madrid, Spain Contact: Juan Manuel Sepúlveda 93 434 44 12 secretaria@geino.es Principal Investigator: Juan Manuel Sepúlveda Hospital Ramón y Cajal Not yet recruiting Madrid, Spain Contact: Mª Ángeles Vaz 93 434 44 12 secretaria@geino.es Principal Investigator: Mª Ángeles Vaz Hospital Regional de Málaga Recruiting Málaga, Spain Contact: Gema Duran 93 434 44 12 secretaria@geino.es Principal Investigator: Gema Duran Hospital Virgen del Rocio Recruiting Sevilla, Spain Contact: Begoña Pérez 93 434 44 12 secretaria@geino.es Principal Investigator: Begoña Pérez 收起 <<
NCT03535506	DCIS	Phase 2	Recruiting	December 31, 2021	United States, District of Col... 展开 >>umbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Nellie Novielli, RN 202-784-3923 noviella@georgetown.edu Principal Investigator: Paula Pohlmann, MD 收起 <<
NCT02501902	Metastatic Pancreatic Ductal A... 展开 >>denocarcinoma 收起 <<	Phase 1	Recruiting	December 27, 2018	United States, Arizona ... 展开 >> Scottsdale Healthcare Hospitals DBA HonorHealth Active, not recruiting Scottsdale, Arizona, United States, 85258 Virginia G. Piper Cancer Pharmacy Active, not recruiting Scottsdale, Arizona, United States, 85258 United States, California UCSD Medical Center - Encinitas Active, not recruiting Encinitas, California, United States, 92024 UC San Diego Medical Center - La Jolla (Thornton Hospital) Active, not recruiting La Jolla, California, United States, 92037-0845 UC San Diego Moores Cancer Center - Investigational Drug Services Active, not recruiting La Jolla, California, United States, 92037-0845 UC San Diego Moores Cancer Center Active, not recruiting La Jolla, California, United States, 92093 UC San Diego Medical Center - Hillcrest Active, not recruiting San Diego, California, United States, 92103 UCSD Medical Center - Vista Active, not recruiting Vista, California, United States, 92081 United States, Colorado Drug Shipment Address: Anschutz Cancer Pavilion Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Cancer Center Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Denver, CTO (CTRC) Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Active, not recruiting Aurora, Colorado, United States, 80045 University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) Active, not recruiting Aurora, Colorado, United States, 80045 United States, Maryland The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231-1000 United States, Massachusetts Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 United States, Missouri Siteman Cancer Center - West County Active, not recruiting Creve Coeur, Missouri, United States, 63141 Barnes-Jewish Hospital Active, not recruiting Saint Louis, Missouri, United States, 63110 Washington University Infusion Center Pharmacy Active, not recruiting Saint Louis, Missouri, United States, 63110 Washington University School of Medicine Active, not recruiting Saint Louis, Missouri, United States, 63110 Siteman Cancer Center - South County Active, not recruiting Saint Louis, Missouri, United States, 63129 Siteman Cancer Center Active, not recruiting Saint Peters, Missouri, United States, 63376 United States, Utah University of Utah, Huntsman Cancer Hospital Active, not recruiting Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Institute Active, not recruiting Salt Lake City, Utah, United States, 84112 Spain Hospital Universitario de Fuenlabrada. Unidad de Farmacia (Only Drug Shipment) Recruiting Fuenlabrada, Madrid, Spain, 28942 Hospital Universitario Fuenlabrada Recruiting Fuenlabrada, Madrid, Spain, 28942 Hospital Universitari Vall D'Hebron Active, not recruiting Barcelona, Spain, 08035 Hospital Universitario 12 de Octubre Servicio de Farmacia Recruiting Madrid, Spain, 28041 Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 收起 <<
NCT03054363	Breast Cancer	Phase 1 Phase 2	Recruiting	October 2020	United States, Arizona ... 展开 >> University of Arizona Recruiting Tucson, Arizona, United States, 85724 Contact: Dana Lewallen 520-626-2175 DLewallen@uacc.arizona.edu Principal Investigator: Pavani Chalasani United States, Colorado University of Colorado Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Tiffany Colvin 720-848-0664 tiffany.colvin@ucdenver.edu Principal Investigator: Elena Shagisultanova, MD, PhD United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Peggy Gilbertsen 312-695-1102 cancertrials@northwestern.edu Principal Investigator: William Gradishar United States, New Mexico New Mexico Cancer Care Alliance Recruiting Albuquerque, New Mexico, United States, 87131 Contact: Karwyn Gustafson 505-925-0380 KSGustafson@salud.unm.edu Principal Investigator: Ursa Brown-Glaberman United States, New York Stony Brook University Recruiting Stony Brook, New York, United States, 11794 Contact: Pushpa Talanki 631-638-0815 Pushpa.talanki@stonybrookmedicine.edu Principal Investigator: Alison Stopeck United States, Texas University of Texas Health Science Center San Antonio Recruiting San Antonio, Texas, United States, 78229 Contact: CTRC 210-450-5798 CTRCReferral@uthscsa.edu Principal Investigator: Andrew Brenner 收起 <<
NCT03065621	Breast Cancer Female	Phase 2	Recruiting	March 2020	Belgium ... 展开 >> Institut Jules Bordet Recruiting Brussels, Belgium, 1000 Contact: Michail Ignatiadis, MD CHU Brugmann Recruiting Brussels, Belgium, 1090 Contact: Jacques Chapiro, MD CU Saint-Luc Recruiting Brussels, Belgium, 1200 Contact: Francois Duhoux, MD UZ Leuven Gasthuisberg Recruiting Leuven, Belgium, 3000 Contact: Patrick Neven, MD CHU UCL Namur Sainte-Elisabeth Recruiting Namur, Belgium, 5000 Contact: Peter Vuylsteke, MD 收起 <<
NCT03123744	Cancer, Advanced	Phase 2	Withdrawn(No study funding ava... 展开 >>ilable.) 收起 <<	February 1, 2024	United States, California ... 展开 >> UCSD Moores Cancer Center La Jolla, California, United States, 92093 收起 <<
NCT03446157	Cancer of the Colon ... 展开 >> Colon Cancer Colon Neoplasms Colonic Cancer Neoplasms, Colonic 收起 <<	Phase 2	Recruiting	July 13, 2023	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27599-7295 Contact: Clinical Trials Office - Lineberger Comprehensive Cancer Cente 877-668-0683 Sub-Investigator: Cheryl Carlson, MD Sub-Investigator: Autumn McRee, MD Sub-Investigator: Hanna Sanoff, MD Sub-Investigator: Tammy Triglianos, RN, NP 收起 <<
NCT02806648	Pancreatic Neuroendocrine Canc... 展开 >>er 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> H.U.C de Asturias Oviedo, Asturias, Spain ICO L'Hospitalet de Llobregat, Barcelona, Spain C. H. de Navarra Pamplona, Navarra, Spain H. Vall d´Hebron Barcelona, Spain H. Castellon Castelló, Spain, 12002 H U Ramón y Cajal Madrid, Spain H. 12 Octubre Madrid, Spain H.U.La Paz Madrid, Spain H.U.Virgen del Rocio Sevilla, Spain 收起 <<
NCT02310243	Acute Myeloid Leukemia ... 展开 >> Acute Lymphoblastic Leukemia 收起 <<	Phase 1 Phase 2	Recruiting	July 2018	Germany ... 展开 >> Klinikum Augsburg Recruiting Augsburg, Germany, 86156 Contact: Christoph Schmid, MD christoph.schmid@klinikum-augsburg.de Helios Klinikum Bad Saarow Recruiting Bad Saarow, Germany, 15526 Contact: Daniel Schöndube, MD daniel.schoendube@helios-kliniken.de Charité Campus Benjamin Franklin Recruiting Berlin, Germany, 12200 Contact: Claudia Bladus, MD claudia.baldus@charite.de Vivantes Klinikum Neukölln Recruiting Berlin, Germany, 12351 Contact: Maike de Wit, MD maike.dewit@vivantes.de Charité Campus Virchow-Klinikum Recruiting Berlin, Germany, 13353 Contact: Jörg Westermann, MD joerg.westermann@charite.de Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Contact: Karin Tina Mayer, MD karin.mayer@ukb.uni-bonn.de Städtisches Klinikum Braunschweig gGmbH Recruiting Braunschweig, Germany, 38114 Contact: Jürgen Krauter, MD krauter.juergen@mh-hannover.de Universitätsklinikum Düsseldorf Recruiting Düsseldorf, Germany, 40225 Contact: Thomas Schroeder, MD thomas.schroeder@med.uni-duesseldorf.de Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH Recruiting Essen, Germany, 45239 Contact: Mohammed Wattad, MD m.wattad@kliniken-essen-sued.de Malteser Krankenhaus St. Franziskus-Hospital Recruiting Flensburg, Germany, 24939 Contact: Nadezda Basara, MD nadezda.basara@malteser.org Universitätsklinikum Freiburg Recruiting Freiburg, Germany, 791016 Contact: Ralph Wäsch, MD ralph.waesch@uniklinik-freiburg.de MVZ Osthessen Recruiting Fulda, Germany, 36043 Contact: Andrea Distelrath, MD distelrath@mvz-osthessen.de Universitätsklinikum Giessen Recruiting Giessen, Germany, 35392 Contact: Maisun Abu Samara, MD maisun.abu.samra@innere.med.uni-giessen.de Universitätsklinikum Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Walter Fiedler, MD fiedler@uke.de Medizinische Hochschule Hannover Recruiting Hannover, Germany, 30625 Contact: Michael Heuser, MD heuser.michael@mh-hannover.de Universitätsklinikum Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Alwin Krämer, MD Alwin.Kraemer@med.uni-heidelberg.de Städtisches Klinikum Karlsruhe gGmbH Recruiting Karlsruhe, Germany, 76133 Contact: Mark Ringhoffer, MD mark.ringhoffer@klinikum-karlsruhe.com Universitätsklinikum Schleswig-Holstein Campus Kiel Recruiting Kiel, Germany, 24116 Contact: Heinz-August Horst, MD h.horst@med2.uni-kiel.de Caritas-Krankenhaus Lebach Recruiting Lebach, Germany, 66822 Contact: Stephan Kremers, MD stephankremers@onkologie-lebach.de Uni-Klinikum der Otto-von-Guericke-Universität Recruiting Magdeburg, Germany, 39120 Contact: Denise Wolleschak, MD denise.wolleschak@med.ovgu.de Universitätsmedizin der Johannes Gutenberg-Universität Recruiting Mainz, Germany, 55131 Contact: Thomas Kindler, MD thomas.kindler@unimedizin-mainz.de Pius Hospital Oldenburg Recruiting Oldenburg, Germany, 26121 Contact: Frank Griesinger, MD frank.griesinger@pius-hospital.de Medizinische Universitätsklinik Tübingen Recruiting Tübingen, Germany, 72076 Contact: Helmut Salih, MD Helmut.Salih@med.uni-tuebingen.de University Hospital of Ulm Recruiting Ulm, Germany, 89081 Contact: Peter Paschka, MD 0049-731-500 ext 45521 peter.paschka@uniklinik-ulm.de 收起 <<

帕博西尼 /Palbociclib {[allProObj[0].p_purity_real_show]}

Palbociclib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Palbociclib 质控信息

Palbociclib 生物活性

Palbociclib 动物研究

Palbociclib 临床研究

Palbociclib 参考文献

Palbociclib 实验方案

Palbociclib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CDK4	CDK4/CyclinD1, IC50:11 nM CDK4/CyclinD3, IC50:9 nM
CDK6	CDK6/CyclinD2, IC50:15 nM

帕博西尼 /Palbociclib {[allProObj[0].p_purity_real_show]}

Palbociclib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Palbociclib 质控信息

Palbociclib 生物活性

Palbociclib 动物研究

Palbociclib 临床研究

Palbociclib 参考文献

Palbociclib 实验方案

Palbociclib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Palbociclib 纯度/质量文件产品仅供科研